The brain attacking itself, mistaking its own genes for a virus
Within the aging brain, fragments of our own genetic past — long-dormant sequences known as jumping genes — are awakening in the presence of disease, producing molecules that the immune system mistakes for viral threats. Researchers at UT Health San Antonio have traced this molecular confusion to the toxic protein tau, linking it to the inflammation that quietly destroys neurons in Alzheimer's disease and progressive supranuclear palsy. The discovery reframes neurodegeneration not merely as a protein accumulation problem, but as a case of the body's defenses turning against a self it can no longer recognize.
- Tau protein, long known as a hallmark of Alzheimer's, is now implicated in awakening dormant genetic elements that flood the brain with inflammatory signals.
- The double-stranded RNA these jumping genes produce is indistinguishable to the immune system from a viral invasion — triggering a destructive response against the brain's own tissue.
- Astrocytes, the support cells that sustain neuronal health and maintain the brain's protective barriers, are the primary sites of this RNA accumulation, making their compromise a critical driver of disease progression.
- Evidence spans human post-mortem brain tissue, fruit fly models, and engineered mice — giving the finding unusual cross-system credibility.
- A Phase II clinical trial is already underway, aiming to silence jumping genes before they can ignite the immune cascade that erodes cognition and kills neurons.
Scientists at UT Health San Antonio have uncovered an unexpected mechanism driving Alzheimer's disease and progressive supranuclear palsy: pieces of our own genome, known as jumping genes or transposable elements, are being reactivated by the toxic protein tau and producing molecules that trick the brain's immune system into a state of chronic inflammation.
In healthy brains, these genetic elements lie dormant. But in the presence of tau — the protein that accumulates abnormally in both diseases — they stir back to life, generating double-stranded RNA that the immune system reads as a viral threat. The result is a self-directed inflammatory attack that progressively damages neurons, even though the trigger originates from the person's own DNA.
Doctoral graduate Elizabeth Ochoa and her mentor Bess Frost, a distinguished professor of neurodegenerative disorders research, published the findings in Science Advances. Their work identified double-stranded RNA accumulating specifically in astrocytes — brain support cells essential for neuronal health and the integrity of the brain's protective barriers. When astrocytes are compromised, the entire environment sustaining neurons begins to deteriorate.
The discovery carries immediate clinical weight. Frost's team is already conducting a Phase II clinical trial aimed at suppressing jumping gene activation in Alzheimer's patients. By mapping the full range of harmful molecules these genes produce, researchers hope to intervene before the immune system's misdirected response can take hold — offering patients and families a therapeutic target where none previously existed.
Researchers at The University of Texas Health Science Center at San Antonio have identified a surprising culprit in Alzheimer's disease and a rare brain disorder called progressive supranuclear palsy: fragments of our own genome that behave like invaders, triggering the brain's immune system to attack itself.
The discovery centers on what scientists call jumping genes, or transposable elements—stretches of DNA that can move around within the genome, copying themselves to new locations. In healthy brains, these elements are largely dormant. But in Alzheimer's disease and progressive supranuclear palsy, both marked by accumulation of a toxic protein called tau, something goes wrong. The tau appears to activate these jumping genes, causing them to produce double-stranded RNA. This abnormal RNA is the key problem: it looks to the immune system like a viral invader, even though it originates from the person's own genetic material.
Elizabeth Ochoa, a recent doctoral graduate, and her mentor Bess Frost, a distinguished professor of neurodegenerative disorders research, published their findings in Science Advances. The work represents a new angle on how these devastating brain diseases progress. "These double-stranded RNAs look like a virus to the immune system even though the jumping genes are a part of our normal genome," Ochoa explained. The implication is stark: the brain's own defense mechanisms, triggered by this molecular mimicry, may be driving the inflammation that damages neurons over time.
The researchers found evidence of this process across multiple systems. They detected accumulation of double-stranded RNA in post-mortem brain tissue from Alzheimer's and progressive supranuclear palsy patients. They also observed it in laboratory models—fruit flies and mice engineered to develop tau-related disease. The RNA accumulated specifically in astrocytes, a type of brain cell that provides critical support to neurons, regulates chemical messengers, and maintains the barrier that protects the brain from harmful substances. When astrocytes are compromised, the entire neuronal environment deteriorates.
Frost noted the significance of this finding for understanding how the brain responds to disease. "In aging and disease, astrocytes respond to injury and disruption of the neuronal environment," she said. The discovery opens questions about how astrocytes normally control these jumping genes and what fails in disease. If researchers can understand that control mechanism, they might be able to prevent the inflammatory cascade that kills neurons.
The work has immediate clinical relevance. Frost and her team are already running a Phase II clinical trial targeting jumping gene activation in Alzheimer's patients. Understanding the full range of toxic molecules these genes produce—including the double-stranded RNA—will be essential to developing effective treatments. The goal is to quiet the jumping genes before they can trigger the immune system's destructive response, potentially slowing or halting the progressive neuronal loss that defines these diseases. For patients and families facing Alzheimer's or progressive supranuclear palsy, this research suggests a new therapeutic target where none existed before.
Citações Notáveis
These double-stranded RNAs look like a virus to the immune system even though the jumping genes are a part of our normal genome.— Elizabeth Ochoa, doctoral researcher, UT Health San Antonio
Transposable elements are a new area of interest in understanding Alzheimer's disease. Our study provides new insights into how they can drive the disease process.— Elizabeth Ochoa
A Conversa do Hearth Outra perspectiva sobre a história
So these jumping genes—they're part of our normal DNA? We all have them?
Yes, everyone does. They're evolutionary remnants, mostly inactive. But in Alzheimer's brains, something reactivates them, and that's when the trouble starts.
And the double-stranded RNA they produce—that's what tricks the immune system?
Exactly. The immune system sees it and thinks there's a viral infection happening. It mounts an inflammatory response. Except there's no virus. It's the brain attacking itself.
Why does tau protein cause this activation? Is that understood?
Not fully yet. That's part of what makes this discovery important—it identifies a new mechanism, but the researchers are still working out the details of how tau triggers the jumping genes in the first place.
And the astrocytes—why are they the cells where this RNA accumulates?
Astrocytes are support cells. They're everywhere in the brain, helping neurons function. If they're flooded with this inflammatory signal, they can't do their job properly. The whole neuronal environment starts to fail.
Is there a way to stop the jumping genes from activating?
That's what the clinical trial is testing. If you can prevent the activation or suppress it early, you might prevent the cascade of inflammation and neuronal death that follows.
How long before we know if it works?
Clinical trials take time. But the fact that they're already in Phase II suggests the early results were promising enough to move forward.